{
    "nctId": "NCT00886535",
    "briefTitle": "Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity",
    "officialTitle": "An Observational Trial of the Effect of Pharmacogenomics Differences in Phase I and II Metabolism of Tamoxifen on Efficacy and Toxicity",
    "overallStatus": "COMPLETED",
    "conditions": "Breast Cancer, Ductal Carcinoma in Situ",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 41,
    "primaryOutcomeMeasure": "Hot flashes",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients receiving tamoxifen for adjuvant therapy of breast cancer or ductal carcinoma in situ, or as chemoprevention\n* Age 18 years and above\n* May be pre- and post-menopausal\n* Females\n* Patients may be at any point in their hormonal treatment, but must have completed any planned surgery, radiation and chemotherapy\n* Must use a reliable form of birth control\n\nExclusion Criteria:\n\n* Pregnant\n* Breastfeeding\n* Concurrent use of corticosteroids, megestrol, or phenobarbital\n* History of allergy to tamoxifen\n* Unwilling to have a yearly gynecological exam",
    "sex": "FEMALE",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}